Business UpdateMay 12, 2026, 07:02 AM
Cartesian Therapeutics to Present at H.C. Wainwright Conference
AI Summary
Cartesian Therapeutics, Inc. announced that its management expects to participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference. The presentation is scheduled for Tuesday, May 19, 2026, at 3:00 p.m. ET, with a live webcast and archived replay available on the company's website. The company is a late clinical-stage biotechnology firm focused on cell therapy for autoimmune diseases, with its lead asset Descartes-08 in various clinical development phases.
Key Highlights
- Cartesian Therapeutics management to participate in H.C. Wainwright 4th Annual BioConnect Investor Conference.
- Fireside chat scheduled for Tuesday, May 19, 2026, at 3:00 p.m. ET.
- Live webcast and archived replay will be accessible on the company's website.
- Cartesian Therapeutics is a late clinical-stage biotechnology company.
- Company pioneers cell therapy for autoimmune diseases.
- Lead asset Descartes-08 is in Phase 3 for generalized myasthenia gravis.
- Descartes-08 is also in Phase 2 for myositis and Phase 1/2 for pediatric autoimmune diseases.
Price Impact
More from RNAC